Permeability of olmesartan medoxomil from lipid based and suspension formulations using an optimized HDM-PAMPA model

Basit Öğe Kaydı
dc.authorid0000-0001-8086-6506en_US
dc.contributor.authorKomesli, Yelda
dc.contributor.authorKarasulu, Ercüment
dc.date.accessioned2022-08-24T07:18:48Z
dc.date.available2022-08-24T07:18:48Z
dc.date.issued2022en_US
dc.departmentFakülteler, Eczacılık Teknolojisi Bilimleri Bölümü, Farmasötik Biyoteknoloji Ana Bilim Dalıen_US
dc.description.abstractHexadecane membrane-parallel artificial membrane permeability assay (HDM-PAMPA) is based on an artificial hexadecane membrane that separates the two compartments (donor and acceptor compartment). This model is used to predict the permeability of drugs in gastrointestinal tract and to simulate the passive absorption. In vivo behaviour of the drugs can be estimated with these systems in drug development studies. In our study we optimized HDM-PAMPA model to determine permeability of olmesartan medoxomil (OM) lipid based drug delivery system (OM-LBDDS). In order to prove that LBDDS formulation facilitates the weak permeability of OM, permeation rates were compared with the OM suspension formula (containing 0.25% v/w CMC). The experiment was performed on a 96-well MultiScreen® PAMPA filter plate (MAIPN4510). The permeability of olmesartan formulations from the donor to acceptor compartment separated by a HDM membrane were determined by the previous validated HPLC method. We created positive control series without coating hexadecane membrane to present the LBDDS and suspension formulation permeability from uncoated plates. The effective permeability constant (Pe) was calculated by the formula and improvement of permeability of OM-LBDDS formulation from hexadecane membrane was confirmed. On the contrary there was no permeation of OM-Suspension in the hexadecane coated plates. As a result, the intestinal permeability of OM-LBDDS was calculated to be at least 100 times more than the suspension. OM-Suspension permeation was only observed in the hexadecane uncoated positive control plates. This was also manifestation of HDM-PAMPA mimicking permeability of intestines because of its lipidic construction.en_US
dc.identifier.citationKomesli, Y., Karasulu, E. (2022). Permeability of olmesartan medoxomil from lipid based and suspension formulations using an optimized HDM-PAMPA model. Pharmaceutical Development and Technology. 10.1080/10837450.2022.2114495en_US
dc.identifier.scopus2-s2.0-85137050572
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://hdl.handle.net/20.500.12939/2954
dc.identifier.wosWOS:000846816800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKomesli, Yelda
dc.language.isoen
dc.relation.ispartofPharmaceutical Development and Technology
dc.relation.isversionof10.1080/10837450.2022.2114495en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBioavailabilityen_US
dc.subjectPermeability Efficiencyen_US
dc.subjectPAMPAen_US
dc.subjectHexadecaneen_US
dc.subjectLBDDSen_US
dc.titlePermeability of olmesartan medoxomil from lipid based and suspension formulations using an optimized HDM-PAMPA model
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu